Tianjin Medical Journal

Tianjin Medical Journal ›› 2026, Vol. 54 ›› Issue (2): 206-210.doi: 10.11958/20251483

• Drug Clinical Evaluations • Previous Articles     Next Articles

Comparison of long-term efficacy and safety of infliximab and ustekinumab in the treatment of moderate-to-severe Crohn's disease

LIN Ping(), WANG Wei, YANG Yong, LIU Ping()   

  1. Department of Gastroenterology, the First People's Hospital of Wuhu City, Wuhu 241000, China
  • Received:2025-04-13 Revised:2025-07-23 Published:2026-02-15 Online:2026-02-12
  • Contact: △E-mail：981260550@qq.com

RichHTML

3

PDF (PC)

11

Abstract:

Objective To compare the long-term efficacy and safety of infliximab (IFX) and ustekinumab (UST) in the treatment of moderate to severe Crohn's disease (CD). Methods Clinical data of 126 patients with moderate to severe CD treated with either IFX or UST were selected, including 84 patients in the IFX group and 42 patients in the UST group. After 54 weeks of treatment, clinical remission rates, clinical response rates, endoscopic remission rates, changes in Crohn's Disease Activity Index (CDAI), Harvey-Bradshaw Index (HBI), Simplified Endoscopic Scoring of Crohn's Disease (SES-CD), laboratory markers, inflammatory bowel disease quality of life (IBDQ) scores, FACIT-F scores and adverse event rates were compared between the two groups. Results There were no significant differences in patient age, gender, body mass index, disease duration, smoking history, previous surgical history, family history or disease location between the two groups of patients (P>0.05). After 54 weeks of treatment, the clinical remission rates in the IFX group and the UST group were 73.8% and 59.5%, respectively, the clinical response rates were 89.3% and 83.3%, and the endoscopic remission rates were 57.1% and 47.6%. There were no significant differences between the groups (P>0.05). After treatment, both groups showed a significant decrease in CDAI, HBI and SES-CD scores (P<0.05), with no significant differences between the groups. Both groups showed a decrease in C-reactive protein and fecal calprotectin levels, and an increase in albumin and hemoglobin levels after treatment in the two groups of patients (P<0.05). There were no significant differences in IBDQ and FACIT-F scores between the two groups of patients, and the incidence of adverse events was similar (P>0.05). Conclusion Both IFX and UST can effectively improve the clinical symptoms and endoscopic inflammation in patients with moderate to severe CD, with good safety. Both treatments can also improve the' quality of life of patients.

Key words: Crohn's disease, infliximab, ustekinumab, efficacy, safety

CLC Number: